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Background: Adrenal ganglioneuroma is a rare tumor constituting 20–30% of all ganglioneuromas. It is a benign
tumor and can present diagnostic problems when confused with other adrenal solid tumors.
Case presentation: We herein report a case of adrenal ganglioneuroma in a 28-year-old Arabic patient and
emphasize the diagnostic role of cross-sectional imaging modalities (computed tomography and magnetic resonance
imaging).
Conclusion: Imaging of adrenal ganglioneuromas is diagnostically challenging. Differentiation between adrenal
ganglioneuroma and other solid adrenal tumors can be difficult. However, some suggestive features on computed
tomography and magnetic resonance imaging are helpful in achieving a correct diagnosis.
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Adrenal ganglioneuroma (GN) is an uncommon benign
neuroblastic tumor comprising Schwann cells and gan-
glion cells [1,2]. It is a rare tumor, constituting 20–30% of
all GNs. Differential diagnosis between adrenal GN and
other adrenal solid tumors is difficult. We herein report a
case of an asymptomatic adrenal GN in a 28-year-old man
and emphasize the diagnostic role of cross-sectional
imaging modalities.Case presentation
A 28-year-old Arabic man was referred to our unit after
the discovery of a right adrenal incidentaloma during a
workup for right subcostal pain. The patient had no other
symptoms. Serum laboratory values included normal
24-hour urinary native catecholamine and metanephrine
levels, normal adrenal corticotrophin and cortisol rhythms,
normal 24-hour urinary free cortisol level, normal adrenal
plasma aldosterone/plasma renin activity ratio, and normal
androgen hormone levels. Computed tomography (CT)* Correspondence: anassmajbar@gmail.com
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unless otherwise stated.showed a well-circumscribed, homogeneous right adrenal
tumor measuring 10 × 7 × 8 cm and exhibiting peripheral
punctate calcifications. The density of this mass on unen-
hanced images was lower than that of muscle (Figure 1).
Additionally, the mass was poorly enhanced with contrast
medium (Figure 2). It was quite large, extending across
the midline and behind the inferior vena cava. It sur-
rounded the right renal artery and came into close con-
tact with the left renal vein. On T1-weighted magnetic
resonance imaging (MRI) (Figure 3), the tumor was
visualized as a homogeneous mass with a signal inten-
sity lower than that of the liver. On T2-weighted MRI
(Figures 4 and 5), the lesion was heterogeneous with a
signal intensity greater than that of the liver. No varia-
tions in the signal intensity were noted on chemical
shift imaging (Figure 6). Poor and delayed tumor
enhancement was observed after intravenous adminis-
tration of gadolinium (Figure 7). Surgical resection was
performed based on suspicion for a nonsecreting adrenal
mass. Surgical exploration revealed a large right adrenal
mass extending across the midline. The mass was com-
pletely resected. Pathological examination of the resected
specimen revealed a mature GN.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 CT without contrast showing an adrenal tumor
with calcifications.
Figure 3 T1-weighted enhanced MRI.
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GN is an uncommon benign and mature neuroblastic
tumor [1]. It is a nonmetabolic tumor that is usually
located along the distribution of the sympathetic nervous
system in the posterior mediastinum (41.5%), retroperito-
neum (37.5%), or adrenal medulla (21.0%) [3,4]. Adrenal
GN is a rare tumor that occurs most frequently in the
fourth and fifth decades of life; in contrast, GN of the ret-
roperitoneum and posterior mediastinum often affect chil-
dren. No sex predominance has been reported, but a
familial disposition and an association with Turner syn-
drome and multiple endocrine neoplasia II have been
identified [5]. Because adrenal GNs usually do not secrete
catecholamines or other hormones, including steroid hor-
mones [5,6], they are often clinically silent and asymptom-
atic, even when large [6]. When symptomatic, the most
frequent clinical features are abdominal pain or palpation
of an abdominal mass.
Histopathologically, GN is entirely composed of gan-
glion cells and Schwannian stroma and does not contain
neuroblasts, intermediate cells, or mitotic figures [4,5].
The presence of neuroblasts indicates that the tumor is
a ganglioneuroblastoma (GNB) or neuroblastoma (NB)Figure 2 CT after contrast enhancement.and excludes GN as a differential diagnosis [4]. However,
NB and GNB may mature to GN.
Most GNs are discovered incidentally on imaging studies
[7,8]. Ultrasonography shows a well-defined, homoge-
neous, hypoechogenic mass [4,9]. CT usually reveals a
homogeneous or slightly heterogeneous mass that tends
to surround major blood vessels without compression or
occlusion. The tumor is well-defined, hypodense, and
poorly enhanced by contrast medium [4,10]. Calcifica-
tions, typically fine and punctate, are seen in approxi-
mately 42–60% of GNs. Early enhancement of linear
septae has been reported, and delayed heterogeneous con-
trast uptake has also been described in some cases. CT
allows for an accurate description of the lesion and its re-
lationship with vascular structures [11].
T1-weighted MRI shows a homogeneous mass with a
signal intensity lower than that of the liver, and T2-
weighted MRI shows a heterogeneous mass with a pre-
dominant signal intensity higher than that of the liver.
T2-weighted MRI also shows no absolute change in
signal intensity on chemical shift imaging. The high,
heterogeneous signal intensity on T2-weighted images
is presumed to be caused by a combination of the myxoid
matrix and relatively low numbers of ganglion cells [4,11].Figure 4 T2-weighted MRI: coronal section.
Figure 5 T2-weighted MRI: axial section.
Figure 6 MRI in–out phase.
Figure 7 MRI after intravenous administration of gadolinium.
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often observed after gadolinium administration. Neither
early nor intense enhancement of GN is typically seen
[4,5,9]. GN, like GNB and NB, may accumulate iodine-
131-metaiodobenzylguanidine; thus, uptake of this agent
does not allow for differentiation among these entities [4].
Preoperative diagnosis is difficult because of the
lack of specific imaging findings [11,12]. Percutaneous
biopsy may help, but the presence of undifferentiated
components limits its utility [10,11]. The differential
diagnosis of adrenal GN includes other adrenal solid
masses such as pheochromocytoma, NB, GNB, adenoma,
and carcinoma [2,4,11]. GNB and NB more frequently de-
velop in children. They exhibit a higher degree of cellular-
ity and a smaller extracellular space than does GN. This is
the main cause of the higher unenhanced density on CT
and a lower hypersignal on T2-weighted MRI. Calcifica-
tions are often punctuate in GN and amorphous in NB
[11]. Pheochromocytoma secretes catecholamines, and
this diagnosis is suspected in younger patients with hyper-
tension. Cross-sectional imaging modalities reveal intense
early enhancement in pheochromocytoma and progressive
delayed enhancement in GN [2].
Certain biological and radiological features should lead
the clinician to consider a diagnosis of GN: no elevated
hormonal secretion; presence of punctuate calcifications,
no vascular involvement, and nonenhanced attenuation
of <40 Hounsfield units on CT; a homogeneous, hypoin-
tense mass on T1-weighted MRI; a heterogeneous, hyper-
intense adrenal mass on T2-weighted MRI; and poor,
delayed enhancement on dynamic MRI.
In conclusion, adrenal GN is a diagnostic challenge on
imaging studies [5]. This tumor is associated with various
diagnostic problems because of its similarity to other solid
adrenal tumors. However, some suggestive features on CT
and MRI are helpful in achieving a correct diagnosis.
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